1235406-85-5

Basic information

• Product Name: tert-Butyl[(5-chloro-2,4-difluorophenyl)sulfonyl]1,3-thiazol-4-ylcarbamate
• Synonyms: tert-Butyl[(5-chloro-2,4-difluorophenyl)sulfonyl]1,3-thiazol-4-ylcarbamate
• CAS NO: 1235406-85-5
• Molecular Formula: C₁₄H₁₃ClF₂N₂O₄S₂
• Molecular Weight: 410.85
• Mol File: 1235406-85-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 491.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.523±0.06 g/cm3(Predicted)
• PKA: -0.37±0.10(Predicted)
• CAS DataBase Reference: tert-Butyl[(5-chloro-2,4-difluorophenyl)sulfonyl]1,3-thiazol-4-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl[(5-chloro-2,4-difluorophenyl)sulfonyl]1,3-thiazol-4-ylcarbamate(1235406-85-5)
• EPA Substance Registry System: tert-Butyl[(5-chloro-2,4-difluorophenyl)sulfonyl]1,3-thiazol-4-ylcarbamate(1235406-85-5)

Safety Data

• Hazardous Substances Data: 1235406-85-5(Hazardous Substances Data)

Upstream product

• 1235406-42-4 thiazol-4-ylaminocarboxylic acid tert-butyl ester 
• 13656-57-0 5-chloro-2,4-difluorobenzene-1-sulfonyl chloride 

Downstream Products

• 1354818-76-0 5-chloro-4-[4-chloro-2-(2-piperazin-1-ylpyrimidin-4-yl)phenoxy]-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide trifluoroacetate 
• 1354819-28-5 tert-butyl [(5-chloro-2-fluoro-4-{2-[3-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl]-4-(trifluoromethoxy)phenoxy}phenyl)sulfonyl]1,3-thiazol-4-ylcarbamate 
• 1354819-07-0 tert-butyl ({5-chloro-2-fluoro-4-[4-fluoro-2-pyridazin-4-yl-5-(trifluoromethyl)phenoxy]phenyl}sulfonyl)1,3-thiazol-4-ylcarbamate 
• 1354819-09-2 tert-butyl ({4-[2-(2-aminopyridin-4-yl)-4-fluorophenoxy]-5-chloro-2-fluorophenyl}sulfonyl)1,3-thiazol-4-ylcarbamate 
• 1354818-85-1 4-[2-(2-aminopyridin-4-yl)-4-fluorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide 
• 1354818-80-6 5-chloro-2-fluoro-4-[4-fluoro-2-pyridazin-4-yl-5-(trifluoromethyl)phenoxy]-N-1,3-thiazol-4-ylbenzenesulfonamide 
• 1354819-08-1 5-chloro-2-fluoro-4-[4-fluoro-2-pyridazin-4-yl-5-(trifluoromethyl)phenoxy]-N-1,3-thiazol-4-ylbenzenesulfonamide 4-methylbenzenesulfonate 
• 1354819-13-8 C₂₈H₂₈ClF₂N₅O₆S₂ 
• 1354818-92-0 4-[2-(5-amino-1H-pyrazol-4-yl)-4-fluorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide 
• 1354819-12-7 C₂₅H₂₁Cl₂FN₄O₅S₂ 
• 1354818-90-8 4-[2-(2-aminopyridin-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide 
• 1354818-94-2 5-chloro-2-fluoro-4-[2-pyridazin-4-yl-4-(trifluoromethoxy)phenoxy]-N-1,3-thiazol-4-ylbenzenesulfonamide 
• 1354818-79-3 5-chloro-2-fluoro-4-[5-fluoro-2-pyridazin-4-yl-4-(trifluoromethyl)phenoxy]-N-1,3-thiazol-4-ylbenzenesulfonamide 
• 1354819-06-9 5-chloro-2-fluoro-4-[5-fluoro-2-pyridazin-4-yl-4-(trifluoromethyl)phenoxy]-N-1,3-thiazol-4-ylbenzenesulfonamide 4-methylbenzenesulfonate 

Relevant articles and documents

Benzenesulfonamide substituted derivative as well as preparation method and application thereof

The invention provides a sulfonamide substituted compound and an application thereof, and particularly provides a compound shown in a general formula I which is described in the specification. The definition of each group is described in the specification

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7

A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective NaV1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction concerns to deliver the desired balance of preclinical in vitro properties. Concerns over nonmetabolic routes of clearance, variable clearance in preclinical species, and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clinical pharmacokinetics. The design strategies and results from preclinical PK and clinical human microdose PK data are described leading to the discovery of the first subtype selective NaV1.7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage sensing domain.

BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula (A-a), or a salt thereof, Where "B1" and "R1" through "R5" are as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (A-a) or their salts, and methods of treating neuropathic pain disorders using the same.